Eupraxia Pharmaceuticals Inc.
TSX:EPRX.TO
4.25 (CAD) • At close November 14, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) CAD.
2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue
| 0 | 0 | 2.979 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cost of Revenue
| 0.058 | 0.05 | 1.489 | 0.05 | 0.049 | 0.049 | 0.055 | 0.05 | 0.049 | 0.039 | 0.041 | 0.03 | 0.02 | 0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit
| -0.058 | -0.05 | 1.489 | -0.05 | -0.049 | -0.049 | -0.055 | -0.05 | -0.049 | -0.039 | -0.041 | -0.03 | -0.02 | -0.02 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit Ratio
| 0 | 0 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Reseach & Development Expenses
| 5.389 | 5.598 | 6.874 | 6.096 | 4.685 | 2.969 | 6.494 | 3.852 | 4.911 | 1.946 | 1.827 | 3.556 | 3.626 | 0.67 | -0.215 | 0.286 | 0.397 | 0.451 | -0.395 | 0.712 |
General & Administrative Expenses
| 2.583 | 2.518 | -0.199 | 2.593 | 2.843 | 1.262 | 2.252 | 0.966 | 1.183 | 1.406 | 1.573 | 1.477 | 1.332 | 4.506 | 0.235 | 0.3 | 0.258 | 0.492 | 0.673 | 0.817 |
Selling & Marketing Expenses
| 0 | 0.86 | 0 | 0 | 0 | 1.828 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SG&A
| 2.583 | 3.378 | -0.199 | 2.593 | 2.843 | 1.83 | 2.252 | 0.966 | 1.183 | 1.406 | 1.573 | 1.477 | 1.332 | 4.506 | 0.235 | 0.3 | 0.258 | 0.492 | 0.673 | 0.817 |
Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.325 | -1.936 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Expenses
| 8.912 | 8.976 | 6.527 | 8.884 | 7.649 | 4.799 | 8.802 | 4.868 | 6.143 | 3.392 | 3.441 | 5.063 | 4.978 | 5.195 | 0.041 | 0.606 | 0.676 | 0.995 | 0.331 | 1.578 |
Operating Income
| -6.555 | -9.027 | -6.349 | -8.624 | -7.445 | -4.847 | -8.575 | -4.675 | -6.028 | -3.356 | -3.41 | -5.043 | -5.288 | -7.131 | -0.062 | -0.606 | -0.676 | -0.995 | -0.331 | -1.567 |
Operating Income Ratio
| 0 | 0 | -2.131 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Other Income Expenses Net
| -1.749 | 0.73 | -4.472 | 2.076 | -0.556 | -0.195 | -0.509 | -0.119 | -0.251 | -0.403 | -0.368 | -0.092 | -0.307 | -3.666 | -0.078 | -0.122 | -0.049 | -0.523 | -0.281 | -0.192 |
Income Before Tax
| -8.304 | -8.296 | -4.315 | -6.548 | -8.001 | -5.042 | -9.083 | -4.795 | -6.28 | -3.76 | -3.777 | -5.135 | -5.595 | -8.862 | -0.14 | -1.062 | -0.99 | -2.153 | -0.713 | -1.759 |
Income Before Tax Ratio
| 0 | 0 | -1.448 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Income Tax Expense
| -0.005 | 0.007 | -0.291 | 0.199 | 0.39 | -0.082 | 0.203 | 0.281 | 0.18 | 0.266 | 0.277 | 0.163 | -0.298 | -1.486 | 0.408 | 0.392 | 0.495 | 0.546 | 0.546 | 0.353 |
Net Income
| -6.007 | -8.15 | -4.096 | -6.314 | -7.827 | -4.96 | -8.823 | -4.656 | -6.09 | -3.691 | -3.718 | -4.974 | -5.437 | -8.86 | -0.138 | -1.06 | -0.983 | -2.146 | -0.735 | -1.745 |
Net Income Ratio
| 0 | 0 | -1.375 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS
| -0.23 | -0.28 | -0.15 | -0.25 | -0.36 | -0.23 | -0.41 | -0.22 | -0.31 | -0.26 | -0.3 | -0.35 | -0.41 | -1.13 | -0.011 | -0.082 | -0.076 | -0.17 | 0 | -0.14 |
EPS Diluted
| -0.23 | -0.28 | -0.15 | -0.25 | -0.36 | -0.23 | -0.41 | -0.22 | -0.31 | -0.26 | -0.3 | -0.35 | -0.41 | -1.13 | -0.011 | -0.082 | -0.076 | -0.17 | 0 | -0.14 |
EBITDA
| -8.912 | -8.976 | -10.519 | -6.065 | -7.396 | -4.799 | -8.519 | -4.625 | -5.98 | -3.317 | -2.644 | -5.014 | -5.268 | -7.111 | 0.313 | -0.585 | -0.34 | -1.091 | -0.135 | -1.517 |
EBITDA Ratio
| 0 | 0 | -2.129 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |